On 2 September 2026, HANSOH PHARMA (03692.HK) announced that the NMPA has accepted the marketing authorisation application for its self-developed B7-H3-targeted ADC HS-20093 for small cell lung cancer after failure of prior platinum-based therapy.
On September 2, 2026, RoboSense (02498.HK) traded lower in the afternoon. As of 15:05, the stock stood at HK$17.39, down 3.39%.
on September 2, 2026, the chip theme continued to weaken, with SMIC (00981.HK) opening lower and trading sideways. As of 13:32, the company was quoted at HKD 68.150, down 1.02%.
on September 2, 2026, the robot theme opened lower and traded sideways, with UBTECH ROBOTICS (09880.HK) continuing to weaken. As of 13:20, the company was quoted at HKD 78.650, down 3.50%.
On 1 September 2026, CSPC PHARMA (01093.HK) announced that SYS6010, its EGFR-targeting antibody-drug conjugate, has been granted another Breakthrough Therapy designation by the NMPA for recurrent or metastatic head and neck squamous cell carcinoma in patients who failed prior immunotherapy and platinum-based chemotherapy. The product has previously received two Breakthrough Therapy designations, and a pivotal Phase III clinical trial of the product as monotherapy for the indication is underway.
On 1 September 2026, CSPC PHARMA (01093.HK) announced that the Phase I clinical trial (SYH2056-001) of SYH2056 tablets for the treatment of major depressive disorder has been officially initiated in China. The product is a small-molecule partial 5-HT2A receptor agonist that demonstrated antidepressant efficacy in animal models with a single dose, and preclinical data indicated low risks of off-target effects, hallucinogenic potential and drug dependence. Participant recruitment and screening are underway.
On September 1, 2026, the three major Hong Kong stock indexes all closed lower. AI concept stocks showed divergent performance on the day, with most weakening, while the chip theme declined across the board. The Hang Seng Index fell 0.93%, the Hang Seng TECH Index fell 1.49%, and the Hang Seng China Enterprises Index fell 0.59%. The intelligent driving space saw divergent moves, with BLACK SESAME (02533.HK) — whose first-half results surged — rising 13.21%, and PONY-W following higher. HORIZONROBOT-W (09660.HK) fell 2.65%, while WERIDE-W and ROBOSENSE followed lower.
NewTimeSpace News: On September 1, 2026, XPENG-W (09868.HK) edged lower in afternoon trading. As of 15:38 HKT, the stock traded at HK$44.64, down 0.58%.
NewTimeSpace (newtimespace.com) News, on September 1, 2026, the chip theme weakened, and HUA HONG GRACE (01347.HK) fluctuated lower. As of 13:35, the stock was quoted at HKD 120.600, down 1.95%.
NewTimeSpace (newtimespace.com) News, on September 1, 2026, the robotics theme weakened, and MIDEA GROUP (00300.HK) fluctuated lower. As of 13:22, the stock was quoted at HKD 100.600, down 0.79%.
NewTimeSpace News: On 1 September 2026, LAEKNA-B (02105.HK) announced that the first subject has been enrolled in the Phase I clinical study of LAE118, a novel PI3Kα pan-mutation selective inhibitor, for advanced solid tumours in China; the drug has received IND approval from the US FDA and CDE, and in June 2026 the Group entered into an exclusive licence agreement with Vasque Bio providing for payments of up to USD 527 million.
NewTimeSpace News: On 31 August 2026, CSPC PHARMA (01093.HK) announced that the Phase I clinical trial of SYH2092 injection, an amylin receptor agonist for weight management in adults who are overweight or obese, has been formally initiated at the first clinical trial centre in China, following the drug clinical trial approval notice obtained from the National Medical Products Administration in August 2026.
NewTimeSpace News: On August 31, 2026, Ocumension Therapeutics (01477.HK) announced that the first patient has been dosed in the Phase III clinical trial of OT-202 (spleen tyrosine kinase inhibitor/vascular endothelial growth factor receptor 2), an investigational treatment for dry eye disease, conducted in China. OT-202 is the Company's self-developed first-in-class drug candidate; its Phase II trial completed enrollment of 213 patients in November 2023, with results published in Ophthalmology and the primary endpoint met in March 2024.
On August 31, 2026, Hong Kong's three major indices closed mixed, with the Hang Seng Index down 0.07%, the Hang Seng TECH Index up 0.32%, and the Hang Seng China Enterprises Index rose 0.27%. Total market turnover for the day was HKD 314.8 billion, with net southbound inflows of HKD 2.139 billion. AI concept stocks diverged on the day, with most large-model names rising and most smart-driving names weakening.
NewTimeSpace News: On 31 August 2026, SHANDONG XINHUA (00719.HK) disclosed that its subsidiary's azithromycin tablets (0.25g) have passed the generic drug consistency evaluation approved by the NMPA; the product is a Class A item of the national medical insurance list with 2025 sales of approximately RMB 670 million in Chinese public medical institutions.
NewTimeSpace News: On August 31, 2026, BIDU-SW (09888.HK) climbed modestly in the afternoon. As of 15:36, the stock traded at HK$96.25, up 0.52%.
